Literature DB >> 29561509

In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding.

Cynthia N Schreiner1, Charles E Ahlfors2, Ronald J Wong2, David K Stevenson2, Diana F Clarke3, Mark Mirochnick3.   

Abstract

We performed an in vitro evaluation of the effect of maraviroc or dolutegravir on bilirubin to albumin binding. At typical treatment and low albumin concentrations, maraviroc had no impact, while dolutegravir affected bilirubin to albumin binding to an equivalent extent as sulfisoxazole. However in vivo, neither is likely to significantly impact bilirubin to albumin binding because of their low concentrations relative to albumin.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29561509     DOI: 10.1097/INF.0000000000002011

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  2 in total

1.  Optimizing Dolutegravir Initiation in Neonates Using Population Pharmacokinetic Modeling and Simulation.

Authors:  Joseph Piscitelli; Mina Nikanjam; Brookie M Best; Edward Acosta; Mark Mirochnick; Diana F Clarke; Edmund V Capparelli; Jeremiah D Momper
Journal:  J Acquir Immune Defic Syndr       Date:  2022-01-01       Impact factor: 3.771

2.  Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.

Authors:  Tom G Jacobs; Koen J van Aerde; Angela Colbers; David M Burger
Journal:  Pediatr Infect Dis J       Date:  2022-02-01       Impact factor: 2.129

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.